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Cryptophycins: cytotoxic cyclodepsipeptides
with potential for tumor targeting
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Cryptophycins are a class of 16-membered highly cytotoxicmacrocyclic depsipeptides isolated from cyanobacteria. The biological
activity is based on their ability to interact with tubulin. They interfere withmicrotubule dynamics and prevent microtubules from
forming correctmitotic spindles, which causes cell-cycle arrest and apoptosis. Their strong antiproliferative activitieswith 100-fold
to 1000-fold potency compared with those of paclitaxel and vinblastine have been observed. Cryptophycins are highly promising
drug candidates, as their biological activity is not negatively affected by P-glycoprotein, a drug efflux system commonly found in
multidrug-resistant cancer cell lines and solid tumors. Cryptophycin-52 had been investigated in phase II clinical trials but failed
because of its high neurotoxicity. Recently, cryptophycin conjugates with peptides and antibodies have been developed for
targeted delivery in tumor therapy. Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.
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Introduction
Cancer represents the second leading cause of death in most
industrialized countries followed by cardiovascular diseases. In
particular, organs like lungs, colon, mammary gland, and prostate
are most often affected. Conventional tumor therapy includes
surgical removal and radiotherapy in the case of locally restricted
tumors as well as chemotherapy when metastases have spread. In
comparison, immunotherapy and gene therapy are not as
frequently applied. In addition, medication is often applied in
palliative treatment to improve quality of life by alleviation of
symptoms for tumor types without any chances for cure. Tumor
therapy is one of the major challenges for modern medicine,
because of the similarity between tumor and healthy cells because
tumors develop from endogenous tissue and do not differ very
much from a non-pathological cell on themolecular level. However,
tumor cells show an accelerated proliferation rate compared with
healthy tissue, and therefore, the enhanced cell division is often
used in a therapeutic approach. In chemotherapy, cell multi-
plication can be restricted or entirely prevented by administration
of neoplastic agents. In fact, antitumor chemotherapeutics often
lack specificity and thus inevitably damage other proliferating cells,
leading to the chemotherapy-associated side effects such as hair
loss, weakening of the immune system, and gastrointestinal
complaints. The selective delivery of antitumor agents to tumor
tissue might provide a solution to overcome systemic toxicity and
undesired side effects. In this context, the drug is linked directly
or through a suitable linker system to a tumor-targeting moiety
(homing device). The use of monoclonal antibodies [1–4],
hyaluronic acid [5,6], small molecules [7] like folic acid [8–10], and
peptides [11–14] as tumor-targeting groups (homing devices) has
been reported. Remarkable progress in cancer therapy has been
made in the last years using such tumor-targeting drug delivery
systems [11,15].
Nature provides a broad range of structurally diverse compounds
with interesting biological properties like taxanes, quinoline
alkaloids, anthracyclines, and epothilones. Such secondary
metabolites provide a pool of pharmacologically promising lead
structures. In particular, inhibitors of mitosis are one of the most
potent classes of anticancer agents available to date [16]. These
compounds can be subdivided into microtubule stabilizers and
tubulin polymerization inhibitors [17,18]. Tubulin is a global
hetero-dimeric protein with α-subunit and β-subunit, which
polymerize to form tube-shaped filaments of approximately 240-Å
diameters, the microtubules [19]. Among other functions,
microtubules are especially important for the formation of the
mitotic spindle and are responsible for the distribution of the
chromatids to daughter cells during cell division [20]. This requires
high dynamics of the microtubule ensured by constant poly-
merization and depolymerization [21,22]. The polymerization
process is guanosine triphosphate (GTP) dependent and, therefore,
depends on the phosphorylation of a nucleotide bound to β-
tubulin, which influences the conformation of the protein structure.
All antimitotic agents have in common that the microtubule
dynamics is disrupted. Therefore, aberrant mitotic spindle formation
leads to mitotic arrest in a prometaphase/metaphase-like state and
to apoptosis. In fact, spindlemicrotubules display 10-fold to 100-fold
more dynamics than interphase microtubules, and thus many
microtubule-targeting compounds act as potent chemotherapeutic
drugs [23]. The majority of the antimitotic drugs bind to one of the
three well-established binding sites on β-tubulin: the vinca domain,
the colchicine site, and the taxane binding site [24]. The vinca
alkaloids vincristine and vinblastine as well as colchicine are
known to prevent tubulin polymerization and reduce, in high
concentrations, the microtubule polymer mass. Upon binding to
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the vinca domain (e.g. of vinca alkaloids, dolastatins, and hemi-
asterlins) or the colchicine binding site (e.g. 2-methoxyestradiol,
methoxybenzenesulfonamide, and combretastatin), respectively,
these agents prevent correct formation of the spindle apparatus
by inhibiting tubulin polymerization. Another mode of action was
found for paclitaxel [25], being the first representative of a
compound class known to act as microtubule stabilizers. Other
natural products have been identified to promote the poly-
merization of tubulin dimers into microtubules and to stabilize
preformed microtubules at high concentrations. These agents
(e.g. taxanes, epothilones, and discodermolide) bind to the
so-called paclitaxel site of tubulin. At low but clinically relevant
concentrations, both tubulin-stabilizing and tubulin-destabilizing
drugs interfere with microtubule dynamics while the microtubule
mass is not affected. In addition, apoptosis is being induced
[26–29]. The cryptophycins, 16-membered cyclic depsipeptides,
were isolated from cyanobacteria Nostoc sp. ATCC 53789 in 1990
by researchers from Merck and were identified as a new class of
microtubule destabilizers (Figure 1) [30]. Treatment of carcinoma
cells with cryptophycin-1 in picomolar concentration quickly leads
to morphological changes of the cells and to apoptosis.
With regard to total synthesis, all naturally occurring
cryptophycins can be divided into the four building blocks unit
A–D being amino or hydroxycarboxylic acids, respectively. Unit A
is an α,β-unsaturated δ-hydroxy carboxylic acid typical for
cryptophycins. In cryptophycin-1, this building block contains a
benzylic β-epoxide, while many cryptophycin derivatives isolated
from Nostoc sp. contain a styrene moiety instead of the styrene
oxide. Such desoxy-cryptophycins are assumed to be biosynthetic
precursors of the corresponding epoxides [31], but their cytotoxic
activities are significantly reduced. In the case of cryptophycin-1, a
D-tyrosine derivative that is O-methylated and chlorinated in 30-
position serves as unit B. Several analogs also contain a second
chloro substituent in the other ortho-position relative to the
methoxy group. The (R)-configuration of unit B is essential for high
cytotoxicity. The relative configuration was proven by X-ray analysis
of cryptophycin-3 [32]. In naturally occurring cryptophycins, unit C
is either β-alanine or (R)-α-methyl-β-alanine, so that cryptophycins
belong to the rare peptidic natural products containing a β2-amino
acid with a chiral center at Cα. Unit D is a α-hydroxy carboxylic acid,
which in many cases is L-leucic acid. In addition, analogs bearing
L-isoleucic acid, L-valic acid, or an α-n-propyl-substituted α-hydroxy
acid subunit have been isolated.
Many cyanobacteria produce toxic secondary metabolites to
protect themselves against other microorganisms [33,34]. The
name cryptophycins was coined because of the high cytotoxicity
of these compounds against yeast of the genus Cryptococcus
[30,35,36]. Moore et al. isolated cryptophycin-1, the first repre-
sentative, from the related Nostoc species GSV 224 and published
a first proposal of the stereochemistry in 1994 [37]. The absolute
configuration of a closely related analog of cryptophycin-1, namely,
arenastatin A, was correctly assigned by Kobayashi et al. [38,39].
Arenastatin A was isolated from the marine sponge Dysidea
arenaria and later renamed to cryptophycin-24. Today, over 28
naturally occurring cryptophycin derivatives have been isolated
(Table 1) [32,40,41], and a large number of synthetic analogs have
been reported in the context of structure–activity relationship
(SAR) studies [42,43]. The ester moieties are susceptible towards
cleavage, and hence linear derivatives of cryptophycins observed
during the methanolic extraction from natural sources represent
artifacts [32]. In biological screening assays, the high cytotoxicity
and cytostatic activity of some representatives of this compound
class were discovered with cryptophycin-1 being the most
efficient one. In addition, cryptophycins display a remarkable
cytotoxicity against multidrug-resistant (MDR) tumor cell lines
[32,37], making this class of natural products interesting as
potential chemotherapeutics [44]. With cryptophycin-52
(LY355703; Figure 1, Table 2), the most promising first-
generation clinical candidate was identified by Eli Lilly [45]. This
synthetic analog displays enhanced stability in aqueous solution
compared with cryptophycin-1, while the high activity against
MDR cells is maintained.
Biological Activity
The exact binding site of cryptophycins and the orientation of
the drug inside the binding pocket are still unknown because no
Figure 1. Naturally occurring antimitotic compounds classified according to their mode of action: (I) microtubule destabilizers (tubulin polymerization
inhibitors) and (II) microtubule stabilizers (microtubule depolymerization inhibitors).
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X-ray structure of a cryptophycin–tubulin complex has been
published yet. Many inhibitors of mitosis interact with tubulin by
binding to one of the three binding sites, namely, the vinca domain,
the colchicine site, or the paclitaxel site. Cryptophycins do not
interfere with binding of paclitaxel or colchicine to tubulin
[45–47]. In contrast, cryptophycins non-competitively inhibit
vinblastine binding to tubulin [44], and identical cleavage patterns
are obtained upon tryptic and chymotryptic digestion of tubulin
treated with cryptophycins and vinblastine, respectively [48]. These
observations suggest that the cryptophycin binding site overlaps
with the vinca domain. Additionally, the structurally diverse
(depsi)peptides cryptophycin, dolastatin-10, hemiasterlin, and
phomopsin A competitively inhibit their interaction with tubulin
assuming a common binding site [49]. This prediction is supported
by combined molecular dynamics simulation and molecular
docking experiments [50] where the β-subunit of the tubulin
heterodimer has been identified as the collective binding site
[44], which is nowadays known as the ‘peptide site’ (Figure 2)
[44,51]. As these peptides are of rather hydrophobic nature, their
binding to tubulin reduces the exposed hydrophobic surfaces
and, therefore, is entropy driven [50,52].
Cryptophycins bearing an epoxide moiety might either bind
covalently to tubulin by nucleophilic attack of an amino acid side
chain to the epoxide or by a non-covalent interaction. The latter
Table 1. Natural cryptophycins isolated by Moore et al. from Nostoc sp. [32,40,41]
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assumption is supported by the fact that cryptophycin-52 can
be recovered from the corresponding tubulin complex after
denaturation of the protein with heat or urea [52]. Moreover, the
concentration of cryptophycin-1 remained the samewhen the drug
was treated with tubulin followed by subsequent precipitation of
tubulin with ethanol. Under these conditions, the solution would
be depleted of cryptophycin-1, if it was bound covalently to tubulin
[53]. Additionally, the epoxide function does not react with lysine,
glutamic acid, dithiothreitol, and β-mercaptoethanol under
physiological conditions because these compounds do not
compromise the ability of cryptophycins to inhibit microtubule
assembly [52,53].
A conformational change of free tubulin dimers occurs upon
binding of cryptophycin [52,54], preventing the polymerization to
microtubules. This even occurs when substoichiometric amounts
of cryptophycin-1 are administered [46]. However, at high drug
concentrations, the tubulin dimers form small ring-shaped
oligomers. Cryptophycins can also associate with the surface of
microtubule ends [55], inducing a conformational change in the
protofilaments, which are cleaved from themicrotubule and cyclize
to tubulin oligomers. Ring structures consisting of eight or nine
tubulin dimers were observed when microtubules were treated
with cryptophycin-1 and cryptophycin-52, respectively [54,56].
Low cryptophycin concentrations lead to a strong suppression of
Figure 2. Representation of the different effector binding sites on β-tubulin (red, colchicine; cyan, taxol; yellow, epothilone; green, cryptophycin) [50].
Table 2. Isosteric replacement of ester bonds and its impact on cytotoxicity of cryptophycin
[98,101–103]
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the microtubule dynamics [53,55]. The disruption of the micro-
tubule dynamics leads to apoptosis (programmed cell death) that
occurs very rapidly without a prolonged mitotic arrest [57,58].
Additionally, the characteristic morphological changes are induced
more quickly with cryptophycin than those of other anti-
proliferative compounds like paclitaxel, cisplatin, and etoposide
[32]. In contrast, cryptophycin disrupts mitotic spindles at
concentrations where no loss of interphase microtubules is
observed [57,59]. As a result of the disturbance of microtubule
dynamics, the apoptosis effector enzyme caspase 3 and the
phosphorylation of Bcl2 are activated. Bcl2 is a regulatory protein
functioning as an apoptosis suppressor. Bcl2-phosphorylation
induced by cryptophycin-52 or its chlorohydrin, cryptophycin-55,
is three orders of magnitude higher than that of paclitaxel [60,61].
Cryptophycins show an extraordinarily high biological activity
both in vitro and in vivo, exceeding that of paclitaxel and vinblastine
by the factor of 100 to 1000. The IC50 values of cryptophycin-1
against various tumor cell lines are in the low picomolar range,
e.g. 4.58 pM against KB cells and 7.63 pM against the LoVo cell line
[37]. In addition, cryptophycins exhibit a very high cytotoxicity
against MDR tumor cell lines. In many cases, expression of P-
glycoprotein (permeability glycoprotein, P-gp), the gene product
of the MDR1-gene, is responsible for the development of resistance
to anticancer agents. This adenosine triphosphate-dependent drug
efflux pump has low substrate selectivity and removes a broad
range of structurally diverse xenobiotics out of the cells, keeping
the intracellular drug concentration at a low level [62]. Polar or
amphiphilic compounds are good substrates for P-gp [63], while
cryptophycins are unpolar and, therefore, rather poor substrates.
In this context, the cytotoxicity of cryptophycins against MDR cell
lines exceeds that of vinblastine, paclitaxel, and colchicines.
In general, cryptophycins have a higher affinity towards tubulin
than other antimitotic compounds [52] and form very stable
drug–tubulin complexes [55]. The stability of such complexes
results in low concentrations of free cryptophycins inside the cells,
and thus, the drug is not a substrate of P-gp. This might also be a
reason for the high activity of cryptophycins against MDR cell lines.
Cryptophycins are also very rapidly up taken by cells and
accumulated inside the cells. In this context, HeLa cells were treated
with 3H-labeled cryptophycin-52 at a constant concentration of
11 pM. Within 20 h, the intracellular drug concentration was
increased to 8 nM, which is 730 times higher than the envi-
ronmental concentration [55]. Their biological activity is maintained
after treatment, and cell growth is inhibited for a longer time after
the end of administration than in the case of paclitaxel and
vinblastine, presumably owing to the tight cryptophycin–tubulin
complex [59,64]. A prolonged delay of tumor growth was observed
for a combination of cryptophycins with other antitumor agents
relying on various modes of action, e.g. paclitaxel (tubulin-
interacting agent), doxorubicin (topoisomerase II inhibitor),
fluorouracil (antimetabolite), or platinum complexes (DNA-dama-
ging agents). The combination therapy was especially effective
when cryptophycin was applied together with a substance of a
different mode of action. In this case, the overall efficiency
exceeded the sum of the individual effects [65].
Hence, cryptophycin-52 is a very active antitumor agent with
superior cytotoxicity compared with many of the conventional
drugs used in oncology. Therefore, cryptophycin-52 was
considered as a potential chemotherapeutic agent, and it was
chosen as the first-generation cryptophycin to undergo clinical
evaluation [66]. Phase I clinical trials indicated that toxicity was
rather linked with the cumulative dose than with schedule
dependence [66,67]. As a result of these studies, cryptophycin-52
was applied as second-line therapy in phase II clinical studies on
treatment of metastatic colorectal cancer and non-small cell lung
cancer where patients had been previously treated with
platinum-based therapy [68]. Unfortunately, a lack of efficacy
in vivo combined with toxicity effects such as arthralgia,
constipation, myalgia, and neuropathy was observed, leading to a
discontinuation of the clinical trials. In particular, the high
neurotoxicity is a major side effect of all currently used antimitotic
drugs because microtubules are essential for cells of the nervous
system. Neurons are the most abundant source of tubulin inside
the body [23]. However, partial response was reported for some
patients with platinum-resistant advanced ovarian cancer, but in
many cases, the observed toxicities prevented the administration
of effectively high doses of cryptophycin-52.
In addition, cryptophycin-55, the chlorohydrin correlate of
cryptophycin-52, and the glycinate of this compound
(cryptophycin-55gly), were found to be highly active in preclinical
trials (Figure 3). Cryptophycin-55 exhibits an improved phar-
macokinetic and rapid distribution into various tissues after
intravenous application into mice. Even a pronounced tumor
selectivity was observed (relative exposure; tumor 80.8%, plasma
3.9%, kidney 3.4%, liver 1.1%, and intestine 2.8%) [69].
Cryptophycin-8, the chlorohydrin of cryptophycin-1, showed high
antitumor activity in vivo against a number of MDR tumors, and
moreover, it was found to be less toxic [70]. In conclusion, the
chlorohydrins are distinguished by promising pharmacokinetics
and a 100-fold to 1000-fold increased antitumor activity compared
with the epoxide parent compounds [71]. It is noteworthy that the
chlorohydrins were found to be converted to the corresponding
epoxides under physiological conditions and in animal studies
[71]. This conversion was also observed in formulation (containing
5% ethanol and 5% cremophor) under different storage conditions,
preventing the formulation of stable solutions. Enhanced stability
as well as improved water solubility of the chlorohydrin
compounds was obtained after esterification with glycine. In
particular, cryptophycin-249 (the glycinate of cryptophycin-8)
shows a high antitumor activity against an MDR mammary tumor
Figure 3. Cryptophycin chlorohydrins and related chlorohydrin glycinates.
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model and has been, therefore, considered as a promising second-
generation clinical candidate [71]. As the glycinate analogs as well
as the chlorohydrins can be converted to the related epoxide-
containing cryptophycins, these derivatives can be considered as
prodrugs of the epoxide parent compound.
Cryptophycin Analogs and SAR Studies
Besides the naturally occurring cryptophycins, numerous synthetic
derivatives have been synthesized for SAR studies to improve
tumor selectivity and water solubility. In this context, the influence
of virtually any structural motif on the bioactivity of this compound
class has been investigated with emphasis onmodifications at units
A and C.
Unit A
The methyl substituent of unit A together with (S)-configuration at
the adjacent stereogenic center is crucial for a high biological
activity irrespective of the substitution pattern of this region
[32,72,73]. The most striking feature of unit A in cryptophycins is
the epoxide moiety, and several analogs with modifications in the
C20–C30 position have been synthesized to clarify its role.
Meanwhile it is accepted that the epoxide is not opened to form
a covalent bond with tubulin; however, this structural motif is of
significant importance for high biological activity. In this regard,
both the presence of the epoxide and the (R,R)-configuration are
essential. The replacement of the epoxide function by a thiirane
leads to a 200-fold reduced cytotoxicity, while replacement by
an aziridine or a trans-styrene provides compounds with
approximately 70-fold lower cytotoxicity (Figure 4) [74]. An even
stronger decrease of the bioactivity was observed after inversion
of the stereochemistry of one or both stereogenic centers: the (S,
R)-configured cis-epoxide [41] is 8000 times less active and the (R,
S)-isomer is 72,500 times less active. In the case of the (S,S)-
configured α-epoxide [72,75], a considerable loss of cytotoxicity
by the factor of 6000 was obtained (Figure 4). The hydrolysis of
the epoxide moiety to the corresponding diol [32] leads to a 500-
fold reduced cytotoxicity in vitro. However, the corresponding
halohydrins obtained after acidolysis of the epoxide function with
HX (X = Cl, Br, I) retain the in vitro activity of the parent compound
[37,76]. Compared with the epoxide-containing cryptophycins, the
analogous chlorohydrins, e.g. cryptophycin-55, exhibit a 100-fold
to 1000-fold increased bioactivity in vivo. Additionally, they are of
outstanding interest because of their wider therapeutic window
[71]. Their stability in aqueous solutions is decreasing with
increasing atomic number of the halogen owing to the higher
reactivity, and over time, the epoxides are regenerated in an
intramolecular SN-reaction [76]. In particular, cryptophycin-55 is
converted to the corresponding epoxide with a turnover of 9%
within 48 h [71].
Stable derivatives of cryptophycin-55 are obtained upon
esterification of the secondary alcohol with glycine (vide supra). It
is noteworthy that they display increased in vivo cytotoxicity [71].
As mentioned earlier, the halohydrins and their glycinate
derivatives can be considered as cryptophycin prodrugs because
they are converted to the biologically active epoxides under
physiological conditions. A library of chlorohydrin esters was
synthesized to evaluate the cytotoxicity in vitro and activity in vivo
based on the substitution pattern of the carboxylic acid [77,78].
While cryptophycin-55gly showed the highest cytotoxicity in vitro,
cryptophycin-249, the chlorohydrin glycinate derived from
cryptophycin-1, had the best activity in vivo against a variety of
MDR tumor cell lines (Figure 3) [71].
Truncated cryptophycins have also been studied based on
cryptophycin-24 (arenastatin A), as a parent compound [79]. These
modifications led to a dramatically reduced cytotoxicity (Figure 5).
The best analog, which contains a para-nitrophenyl substituent,
showed a strong inhibition of α-tubulin and β-tubulin owing to
the binding to β-tubulin in the same manner than other
cryptophycins.
Modifications of the phenyl ring of unit A in cryptophycin-52
were another focus of SAR studies (Figure 6). A methyl substituent
in meta-position or a meta-methyl substituent and a para-methyl
substituent have only a limited influence on cytotoxicity, which is
marginally decreased by a factor of 7 or 2, respectively. In contrast,
a methyl group in both ortho-position and para-position results in
20,000-fold reduced activity, and the corresponding analog is
almost inactive. Additionally, the exchange of the phenyl ring
against a methyl substituent or a thiophene ring leads to decreased
bioactivities [74]. The para-hydroxy functionalized cryptophycin-51
derivative exhibits a significantly reduced bioactivity, which,
however, most likely is due to the missing epoxide moiety [77,80].
The low water solubility of cryptophycin-52 is one of its major
drawbacks, and therefore, more polar cryptophycin-52 unit A
analogs have been investigated. The introduction of a para-
hydroxymethyl group results in a 5-fold to 10-fold increased activity
against the human leukemia cell lines CCRF-CEM [80] and HL-60
[77], but at the same time, the activity against the MDR subclone
HL-60/Vinc is decreased by a factor of 27. Three para-alkoxymethyl
analogs have been synthesized, aiming to improve bioactivity and
Figure 4. Structures and cytotoxicities of cryptophycins with modified epoxide moieties (IC50 values in nM). Parent compounds: (a) cryptophycin-1, (b)
cryptophycin-52, (c) cryptophycin-51, (d) cryptophycin-55. Cell lines: KB, human cervical carcinoma; B16V, murine melanoma; LoVo, human colon carcinoma.
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water solubility, while the high activity of cryptophycin-52 against
MDR cells is retained [81]. These derivatives were evaluated using
the non-MDR human cervical carcinoma cell line KB-3-1 and its
MDR subclone KB-V1. Best results were obtained for the para-
methoxymethyl analog, which is more cytotoxic than the parent
structure. However, it is also a slightly better substrate for P-gp in
the KB-V1 cells, which leads to a fivefold decreased activity against
this MDR cell line. The cytotoxicity of the para-isopropoxymethyl
analog is comparable with that of cryptophycin-52, while
the activity against the MDR cells was reduced by a factor of 3.5.
Figure 5. Structures and cytotoxicities of cryptophycin with truncated epoxide chain (IC50 values in μM). Cell lines: A549, lung cancer; PC-3, cervical cancer.
Figure 6. Cytotoxicities of unit A-modified cryptophycin-52 analogs (IC50 values in nM). Cell lines: CCRF-CEM, human T-cell leukemia; HL-60, human acute
myelocytic leukemia; HL-60/Vinc, P-gp-expressing vincristine-resistant subclone of HL-60; HL-60/Adr, MRP1-expressing adriamycine-resistant subclone of
HL-60; KB-3-1, human cervical carcinoma.
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The para-tert-butoxymethyl analog exhibits slightly decreased
bioactivities against both cell lines presumably owing to the steric
bulk of the alkoxy substituent. The resistance factor of an MDR cell
line for a specific drug is defined as the ratio of IC50 values for the
MDR cell line and the non-resistant cell line. Hence, it is a measure
for reduced cytotoxicity by resistance mechanisms.
Amino derivatives are very active in vitro, but in vivo experiments
in mouse model show high systemic toxicity and, therefore, a
narrow therapeutic window [80]. Polar substituents increase water
solubility and lead to an enhanced biological activity of the
corresponding cryptophycin derivatives on the one hand [77,80],
but on the other hand, such polar analogs display reduced
cytotoxicity against MDR tumor cell lines compared with the parent
structure cryptophycin-52 [77]. The transmembrane ABC trans-
porter P-gp is reported to prefer hydrophobic or slightly cationic
substrates [82,83]. In this context, cell lines expressing P-gp, e.g.
HL-60/Vinc cells, show a very strong resistance against the polar
modified cryptophycins, while HL-60/Adr cells that express the
MRP1-transporter are barely resistant against these analogs.
Consequently, polar substituents at the phenyl ring are assumed
to render cryptophycins into better substrates of the P-gp efflux
pump [77]. Amino-functionalized cryptophycins exhibit particularly
high resistance factors.
Unit B
The native 3-chloro-O-methyl-D-tyrosine building block of
cryptophycin-1 and cryptophycin-52 is indispensable for high
biological activity. Modifications at unit B with small polar
substituents are tolerated to a certain extent but in general lead
to less active analogs [32,41,75]. Improved cytotoxicity by variation
of the native unit B fragment could not yet be achieved. In this
regard, the exchange of the 3-chloro-4-methoxyphenyl residue by
a phenyl ring results in an eightfold decreased bioactivity
(Figure 7). Homologation with an additional methylene group leads
to a 3000 times less active analog compared with the phenyl
modified compound. The chloro substituent is also important for
cryptophycin-1 analogs, as its omission leads to eightfold
decreased bioactivity, while a more significant loss is observed
when an additional chloro substituent is introduced in ortho-
position to the para-methoxy group [75,84]. The cytotoxicity of
cryptophycin-1 is also decreased significantly when both the O-
methyl group and the chloro substituent are omitted. A less
significant decrease is observed for an additional chloro
substituent, which is in ortho-position to the hydroxyl group. Similar
results are obtained in case of a phenyl ring substitutedwith a para-
amino group. Such an analog shows a 460-fold decreased
cytotoxicity, while the corresponding derivative with para-amino
group and an adjacent chloro substituent gave only a 26-fold loss
of activity. Interestingly, high biological activity is observed for the
chloro substituted para-dimethylamino analog, for which the
cytotoxicity is reduced by only a factor of 2.5 compared with that
of cryptophycin-52. The replacement of the aryl group against
structurally aberrant aryl or alkyl residues, for example, a cyclohexyl
ring, results in a substantial loss of activity; an even bigger loss is
observed in the case of the α-naphthyl and β-naphthyl substituted
cryptophycins. Inversion of the stereochemistry at Cα results in an
almost inactive cryptophycin-24 analog [72].
Two cryptophycin analogs with an elongated unit B fragment
have been reported (Figure 8) [85]. The Arndt–Eistert reaction
Figure 7. Structure–activity relationship studies of unit B building block (IC50 values in nM). Parent compounds: (a) cryptophycin-1, (b) cryptophycin-52, and
(c) cryptophycin-24. Cell lines: CCRF-CEM, human T-cell leukemia; KB, human cervical carcinoma.
Figure 8. Cryptophycin analogs with an elongated unit B building block (IC50 values in nM) [85]. Cell lines: K562, multidrug-resistant human leukemia; LoVo,
human colon carcinoma.
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served as the key step in the synthesis of the corresponding
homologated unit B building block, a β-amino acid. At the same
time unit C, natively a β-amino acid was replaced by the α-amino
acids D-alanine or D-methionine, respectively. This keeps the size
of the macrocycle constant but virtually shifts the amide group.
Simultaneously, the ester bond between units C and D was
replaced by a more stable amide bond. Moreover, both analogs
lack the β-epoxide, which might explain the low cytotoxicities
observed against 15 cell lines. In each case, the IC50 value exceeded
3 μM, adding further proof that modifications at unit B result in a
significantly reduced bioactivity.
Conformational analysis of cryptophycin derivatives revealed a
trans-amide bond between units B and C both in solution and in
solid state, while a cis-amide bond prevails between units A and B
[32]. Although size and dipole moment of 1,4-disubstituted triazole
rings are larger in comparison with trans-amide bonds [86], these
triazole rings have been suggested to act as trans-amide mimetics
because they exhibit almost identical physicochemical pro-
perties [87]. Furthermore, the triazole ring is metabolically inert
because it cannot be hydrolytically cleaved, oxidized, or reduced
under physiological conditions [88]. The bioisosterism of 1,4-
disubstituted 1H-1,2,3-triazoles and trans-amide bonds have been
proven in many cases [89–91], and therefore, the peptide bond
between units B and C was replaced by a 1,4-disubstituted triazole
ring to corroborate this bioequivalence (Figure 9) [92]. For the
synthesis of such a cryptophycin-52 triazole analog, an alkyne-
functionalized unit B building block was coupled via CuI-catalyzed
azide–alkyne cycloaddition to an appropriate azide-modified unit
C fragment. Indeed, the high biological activity of cryptophycin-
52 was largely maintained for the corresponding triazole analog:
The cytotoxicity of the triazole analog (IC50 = 3.2 nM) against the
P-gp-expressing MDR cells KB-V1 decreased by fivefold only
compared with cryptophycin-52 (IC50 = 0.7 nM) [92]. This
preservation of cytotoxicity for the triazole analog is remarkable
because the 16-membered macrocycle of cryptophycin-52 is
extended to a 17-membered ring.
Unit C
Natural cryptophycins contain either (R)-β-aminoisobutyric acid
(e.g. cryptophycin-1) or the α-unsubstituted building block β-
alanine (e.g. cryptophycin-24). Upon extraction of cryptophycins
from their natural sources, Moore and co-workers observed acyclic
products by methanolysis, giving the first hint that the ester bond
between units C and D might be sensitive towards hydrolysis [32].
In this context, cryptophycin-24 is hydrolysis sensitive under
physiological conditions owing to the absence of an α-substituent
and, hence, shows a half-life period of only 10 min in mouse serum
[93]. Additionally, the in vivo activity is marginal. With increasing
steric shielding of this ester bond by additional adjacent
substituent, the stability of the corresponding cryptophycins
increases and, therefore, cryptophycin-1 is more stable in vivo and
exhibits a higher in vivo activity than cryptophycin-24.
In order to enhance the stability of cryptophycins by increasing
the steric demand of the unit C–D ester bond, different α,α-
dialkylated β-amino acids (β2,2-amino acids) have been
incorporated as unit C building blocks into the cryptophycin
macrocyle (Figure 10) [94]. The exceptionally potent analog
Figure 9. The cryptophycin-52 triazole analog can be considered as a
mimic of the trans-amide parent structure (IC50 values in nM) [92].
Figure 10. Structure–activity relationship studies of unit C building block (IC50 values in nM). Parent compounds: (a) epoxide and (b) chlorohydrin. Cell lines:
CCRF-CEM, human T-cell leukemia; GC3, human colon carcinoma; KB, human cervical carcinoma [32,94,95].
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cryptophycin-52 bears an α,α-dimethyl substituent. The related
chlorohydrin, cryptophycin-55, also exhibits a high in vitro
cytotoxicity, while the corresponding α,α-diethyl compounds
display 30-fold to 50-fold less activity. The biological activity is
further decreased by a factor of 175 to 400 in case of the α,α-di-n-
propyl analogs. One might assume that the interaction of the
higher substituted analogswith tubulin is hindered by steric effects.
Additionally, the water solubility of these analogs is reduced with
increasing lipophilicity leading to lower efficiency. The same
tendency is observed for the corresponding cyclopropyl-
substituted, cyclopentyl-substituted, and cyclohexyl-substituted
spiro compounds. In particular, the cyclopropyl analog of
chlorohydrin cryptophycin-55 shows an activity comparable with
that of its parent. Considerably lower in vitro cytotoxicities are
observed for the higher substituted spiro compounds [94]. While
the in vitro activity of cryptophycin-1 could be improved with the
analogs cryptophycin-52 and cryptophycin-55, the same is not
generally true for the in vivo activity [77].
Shifting the methyl substituent of unit C of cryptophycin-1 from
the α-position to the β-position seems to influence the in vitro
activity for the cryptophycin-1 analog with an epoxide in unit A,
but not for the related chlorohydrin. However, with an increasing
steric demand of the alkyl or aryl residues at the β-carbon atom,
the in vitro cytotoxicity is more and more decreased [95]. In
addition, the in vivo activity of the α-unsubstituted analogs in
mouse serum was low as well because of the hydrolytic instability
of the sterically non-shielded unit C–D ester bond. Introduction of
the α,β-disubstituted unit C building block cis-2-amino-
cyclohexanoic acid results in a sevenfold decreased cytotoxicity,
while the conformationally restricted 2-aminobenzoic acid analog
is virtually inactive [95].
Replacement of the unit C β2-amino acid by various α-amino
acids leads to a drastic loss of activity [95]. The incorporation of L-
alanine results in a 30-fold to 50-fold less active analog, while the
cytotoxicity decreases dramatically in the case of the higher
substituted L-amino acids valine, leucine, phenylalanine, and
proline. The corresponding cryptophycins are almost inactive
presumably because of the constricted 15-membered macrocycle,
which is not able to adopt the required conformation for an
efficient interaction with tubulin.
Recently, the synthesis and biological evaluation of
cryptophycin-1 analogs modified by polar unit C building blocks
were reported (Figure 11) [96]. Additionally, the influence of the
stereochemistry at the α-position of this fragment was investigated.
Many of these analogs prove to be highly active against KB-3-1 cells
with IC50 values in the picomolar range. However, the IC50 values
against the MDR subclone KB-V1 are only in the nanomolar range
compared with cryptophycin-52 (IC50 = 0.7 nM). The amphiphilic
nature of these cryptophycins presumably makes them better
substrates for the P-gp efflux pump.
In summary, there is a certain tolerance concerning the
introduction of moderately bulky, non-polar alkyl substituents into
the native unit C building block. Particularly, the steric hindrance of
the labile unit C–D ester bond by two geminal methyl groups in the
α-position is favorable. However, the bioactivity decreases with
increasing alkyl residues. There is no clear-cut tendency regarding
the stereochemistry. The β-amino acid framework is substantial
for the active 16-membered macrolide structure and to provide
the necessary conformational flexibility. The polar unit C
functionalized cryptophycins show high cytotoxicities against KB-
3-1, but they are less active against MDR tumor cells.
Unit D
Unit D modifications have not yet been investigated extensively,
although it has been observed that some variation in that region
is tolerated. With this regard, even cryptophycins isolated from
natural sources contain one of four different α-hydroxy acids as
the unit D fragment. Themost potent cryptophycin derivatives bear
an isobutyl group, but the alternative sec-butyl, isopropyl, and n-
propyl residues lead to only slightly decreased cytotoxicities
(Figure 12) [32]. Interestingly, the bulky non-natural neopentyl
group proved to be equally as effective in vivo as the isobutyl
residue [65]. Furthermore, unit D is the only building block of the
cryptophycin backbone in which inversion of the stereochemistry
does not have an extremely deleterious effect, although naturally
Figure 12. Structure–activity relationship studies of unit D building block (IC50 values in nM) [32,65,97,98]. Parent compounds: (a) cryptophycin-1, (b)
cryptophycin-24, and (c) cryptophycin-3. Cell lines: KB, human cervical carcinoma; MCF-7, human breast adenocarcinoma.
Figure 11. Polar functionalized unit C analogs of cryptophycin-1 and the corresponding cytotoxicities (IC50 values in nM) [96]. Cell lines: KB-3-1, human
cervical carcinoma; KB-V1, P-gp-expressing multidrug-resistant subclone of KB-3-1.
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occurring cryptophycins exclusively possess L-configured α-
hydroxy acids [97]. A cryptophycin-24 analog with (R)-configuration
at unit D was almost as potent against MCF-7 cells as the (S)-
configured natural parent. By contrast, a significant reduction
of bioactivity by the factor of 40,000 was found when an achiral
α,α-disubstituted unit D fragment was incorporated into
cryptophycin-24 [98]. It can be excluded that the low activity results
from a labile ester bond between units C and D because this analog
was stable in mouse serum, but rather it can be concluded that the
alkyl side chain of unit D is involved in the interaction of
cryptophycin with tubulin.
More recently, the synthesis of two cryptophycins with functional
groups in unit D was reported (Figure 13) [99]. The allyl ester
protected analog can be considered as the precursor for the free
acid derivative, and the deprotection step using Pd(PPh3)4
catalyzed allyl transfer to morpholine provided the cryptophycin
analog with a free carboxy group in good yield. Both unit D
cryptophycin analogs containing an allyl ester or a free carboxylic
acid show high activities against the KB-3-1 cells with IC50 values
of 14.5 or 88.6 pM, respectively. In the case of the P-gp-expressing
MDR cell line, the allyl ester modified analog (IC50 = 0.66 nM)
remains highly potent, while the cytotoxicity of the free acid
cryptophycin (IC50 = 372 nM) is reduced by a factor greater than
1000. This analog might be a better substrate for P-gp owing to
the increased amphiphilicity [100].
Isosteric Replacement of Ester Bonds within
the Cryptophycin Backbone
In order to enhance the stability of cryptophycins towards
hydrolysis, labile ester bonds were substituted by more
stable functionalities (Table 1). The ester bond between units
C and D can be replaced by an amide bond without com-
promising cytotoxicity, because the corresponding derivatives
of cryptophycin-1, cryptophycin-8, cryptophycin-52, and
cryptophycin-55 are almost as potent as the parent compounds
[101]. However, an ether bond at the same position is tolerated
to a minor extent, and such cryptophycin analogs exhibit 50-fold
to 100-fold reduced cytotoxicities presumably owing to the
missing hydrogen bond accepting carbonyl group.
Replacement of the ester bond between units C and D by a more
stable amide bond in case of cryptophycin-24 results in a 1,200-fold
decreased bioactivity [98,102]. A thioester bond at the same
position does not affect cytotoxicity as much, and the corres-
ponding cryptophycin-24 analog is 180-fold less active than the
parent structure [98], although the thioester is even more
hydrolysis sensitive in mouse serum than the analogous ester. In
contrast, the exchange of the same ester bond by a 4-deoxy
methylene ketone leads to a hydrolytically stable compound, but
the bioactivity drops by a factor of 14,000. When the ester bond
between units A and D is replaced by an amide bond, a 800,000-
fold less active analog is observed. The labile C–D ester bond is still
present in this compound, presumably causing the low activity, and
additionally, this isoster is poorly water soluble [102]. The
replacement of both ester bonds by amides leads to a cyclopeptide
analog, which is completely inactive [102]. This compound is
extreme hydrolytically stable but almost insoluble in polar solvents
like water, dimethylsulfoxide, or alcohols, which might be the
reason for the missing activity. It is noteworthy that such
cryptophycin-24 amide that contains polar unit A building blocks
are both significantly more water soluble and more potent in vitro
as well as in vivo [103].
Fluorinated Cryptophycins
Elementary fluorine is very rare in nature owing to its high redox
potential. Consequently, and because of the low abundance of free
fluoride ions in the environment comparedwith chloride ions, there
are only very few naturally occurring fluorinated compounds
known [104]. One of the first synthetic fluorinated pharmaceuticals
is the antineoplastic agent 5-fluorouracil, which was reported for
the first time in 1957 and brought to market by Hoffmann-La Roche
in 1962. Since then, fluorinated drugs have becomemore andmore
important over the last decades, and presently, more than 20% of
all pharmaceuticals contain at least one fluorine atom [105–107].
Fluorination is supposed to improve bioavailability and receptor
selectivity [108]. Hydrogen can be exchanged by fluorine without
significant changes of the molecular size or shape because of the
similar van der Waals radius [109]. The high electronegativity of
fluorine substituents substantially affects the electronic properties
of the parent compound.
Moore et al. reported the total synthesis of analogs of
cryptophycin-1 and cryptophycin-52 fluorinated in unit A
(Figure 14) [110]. Derivative B bearing a fluorine substituent in
para-position proved to be remarkably active with an IC50 value
of 39 pM against the human cell line KB-3-1. Hence, its in vitro activity
is well comparable with that of cryptophycin-1 (IC50 = 29 pM) [111].
Additionally, the chlorohydrin of compound E (IC50 = 33 pM, CCRF-
CEM), an analog based on cryptophycin-52 (IC50 = 22 pM, CCRF-
CEM), was patented by Eli Lilly as a very promising clinical candidate
[112]. The same research group produced the unit B fluorinated
cryptophycins F and G by fermentation (Figure 14). For this
purpose, strains of Nostoc sp. were cultivated in media enriched
with the appropriate phenylalanine derivatives, which served as
precursors for the unit B building blocks. However, the biological
activity of these analogs against KB-tumor cells has not been
explicitly described.
Cryptophycin-52 analogs with more than one fluorine subs-
tituent have recently been published (Figure 15) [113]. The CF3-
functionalized compound is about fivefold less active against the
tumor cell line KB-3-1 in comparison with cryptophycin-52, while
the pentafluorophenylalanine analog shows a significant loss of
cytotoxicity, most likely owing to the absence of the methoxy
group. Substantially lower activity was noted for both derivatives
against the MDR subclone KB-V1. The amphiphilicity presumably
leads to increased clearance by the P-gp efflux pump. Despite
reduced activity in vitro, it would be very interesting to evaluate
in vivo cytotoxicity of these analogs and to further investigate the
influence of fluorine substituents.
Figure 13. Unit D-modified cryptophycin-52 analogs with functional
groups in the side chain for bioconjugation and prodrug design [99]. Cell
lines: KB-3-1, human cervical carcinoma; KB-V1, P-gp-expressing multidrug-
resistant subclone of KB-3-1.
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Cryptothilone 1 – A Cryptophycin–Epothilone
Hybrid
Cryptophycins and epothilones are both very potent antimitotic
natural products that inhibit cell proliferation by interfering with
tubulin polymerization. However, they are of largely different origin.
While cryptophycins have been isolated from cyanobacteria
[30,37,59], the latter originate from the myxobacteria Sorangium
cellulosum [114]. It is noteworthy that they bind to different
sites of the microtubule and differ in their effect on tubulin
polymerization. As described earlier, the cryptophycin family acts
as microtubule destabilizers binding to the ends of microtubules
and, hence, leads to degradation of the tubulin polymers. In
contrast, epothilones are microtubule stabilizers known to bind to
an interior region of the microtubule adjacent to the taxol binding
site. Epothilones reduce the dissociation rate of tubulin dimers
upon binding to the β-subunit of tubulin while acting as a stapling
device and stabilizing the polymeric structures.
Comparing the structural features of natural cryptophycin-4 and
trans-epothilone C, a synthetic analog with similar tubulin
polymerization properties compared with the natural 12,13-cis
isomer, striking similarities along with one significant difference
become obvious (Figure 16) [115]. Both compounds have in
common (i) a 16-membered ring, (ii) an aryl substituent joined to
a conjugated double bond (that is epoxidized in some
cryptophycin analogs), (iii) a methyl substituent at or in close
proximity to the conjugated double bond, (iv) an (S)-configured
stereogenic carbon with an oxygen substituent to involved in
lactonization, and (v) an alkene (which is epoxidized in epothilones
A and B) segregated from the acyloxy carbon by one methylene
moiety. Besides these similarities, the cryptophycin segment
comprising the two amide bonds is rather rigid, albeit the C8–C11
region of epothilones is quite flexible. A hybrid structure
comprising the similarities was synthesized to evaluate the different
tubulin binding modes typical for each compound class.
Cryptothilone 1 encloses the upper half of cryptophycin-4 and the
lower part common to most epothilones (Figure 16) [115].
However, this type of hybrid molecule turned out to be inactive
with respect to interfering with tubulin polymerization or
depolymerization at concentrations up to 40 μM. Hence, it is
assumed that this compound has affinity neither for the
cryptophycin nor for the epothilone/taxol binding site.
Cryptophycin Conjugates
Practically all cytotoxic agents that may be used in tumor therapy
do not display any selectivity between healthy tissue and tumor
tissue, as the cytotoxic agent targets cellular structures like
microtubules or DNA. Consequently, many cytotoxic agents display
a very narrow therapeutic window and, hence, cannot be applied in
tumor therapy. Conjugates of cytotoxic agents (also called
‘payload’) and a homing device that would direct the conjugate
selectively to tumor tissue have been designed to overcome this
problem. As homing devices, monoclonal antibodies, peptides,
and small molecules have been proven amenable. In particular,
antibody–drug conjugates (ADCs) have been emerging as a novel
therapeutic concept [2–4]. The homing devices selectively address
receptors that are overexpressed on the tumor cell surface. Upon
binding of the conjugates to the target receptor, these complexes
Figure 14. Fluorinated analogs of cryptophycin-1 and cryptophycin-52 [110–112].
Figure 15. Highly fluorinated cryptophycin-52 analogs and the accompanying cytotoxicities (IC50 values in nM) [113]. Cell lines: KB-3-1, human cervical
carcinoma; KB-V1, P-gp-expressing multidrug-resistant subclone of KB-3-1.
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are internalized by the cell, e.g. by receptor-mediated endocytosis.
Ideally the conjugates do not display significant cytotoxicity, but
the toxic payload is being liberated in the lysosomes after
endocytosis. This strategy enables the application of highly toxic
compounds that would otherwise also damage healthy cells.
Having failed in clinical phase II studies, cryptophycin-52 still
remains a promising cytotoxic agent, provided targeted delivery
to tumor cells can be achieved. A conjugate involving folic acid as
the targeting device together with a polar linker, a disulfide moiety
for intracellular release, and a carbonate based on cryptophycin-55
has been claimed by Endocyte (Figure 17) [116]. The folate-based
conjugates address cancer cells as they are known to overexpress
folate receptors. The IC50 value against KB cells was in the low
nanomolar range and cytotoxicity could be competed against by
the addition of free folate.
The aromatic ring of unit A in cryptophycin-52 can be subjected
to modification in para-position without significantly compro-
mising biological activity. Thesemodifications have been employed
by Sanofi-Aventis as attachment points for antibody conjugation
[117,118]. Either cleavable or non-cleavable linkers were used to
connect the cytotoxic payload and the antibody hu2H11, a
monoclonal antibody addressing the EphA2 receptor (Figure 18).
Some conjugates display sub-nanomolar cytotoxicity against the
breast gland cancer cell-line MDA-MB-231, which can be competed
against by free antibody.
Genentech has also used the para-position of the aromatic ring
of unit A as a handle for the conjugation to an antibody [119].
Specifically, the payload was conjugated to the cysteine mutant
A118C that targets HER2 and CD22 receptors (Figure 19). The
conjugates displays sub-nanomolar cytotoxicity against cell lines
Figure 16. Structural homology of cryptophycin-4 and trans-epothilone C as well as the hybrid molecule cryptothilone 1.
Figure 17. Cryptophycin conjugate with folic acid as the homing device [116].
Figure 18. Antibody–drug conjugates with a cryptophycin-52 derivative modified in unit A connected across a cleavable tert-butylthio linker to the
monoclonal antibody hu2H11 [117,118].
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overexpressing HER22 or CD22 receptors, while they are inactive
with cell lines that do not overexpress these receptors.
More recently, the use of cryptophycin-55 glycinate as a
prodrug has been acknowledged in a patent [120]. The
cryptophycin-55 glycinate has been conjugated to the antibody
trastuzumab, which targets HER2 receptors, through a cleavable
linker (Figure 20). The conjugate displayed nanomolar activity
against SK-BR3 cells and inactivity in other cell lines that were
not expressing the HER2 factor.
Peptides might represent a viable alternative to protein-based
homing devices. Peptides can be obtained by chemical synthesis
and are, therefore, easier to purify than recombinant proteins. For
targeting purposes, RGD peptides have been envisaged. A
conjugate comprising a cyclic RGD peptide connected across a
modified carboxyfluorescein residue to a unit C modified crypto-
phycin (Figure 21) has been proven to bind to the integrin αVβ3 that
is highly expressed on some tumor cells [96]. The complex
undergoes internalization by integrin-mediated endocytosis.
Confocal microscopy studies with this conjugate and WM-115
human epithelial cancer cells proved the lysosomal localization of
the fluorescent conjugates. This result shows that integrin αVβ3 is
a suitable target structure for tumor targeting.
The prodrug cryptophycin-55 glycinate has also been used to
prepare a conjugate with octreotide peptide (Figure 22) [120].
Figure 20. Antibody–drug conjugates with a cryptophycin-55 glycinate as a prodrug that targets HER2 receptors [120].
Figure 19. Antibody–drug conjugates with a cryptophycin-52 derivative modified in the unit A that targets HER2 and CD22 receptors [119].
Figure 21. Conjugate of a cryptophycin modified in unit C with a fluorescently labeled RGD peptide [96].
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Octreotide targets somatostatin receptor subtypes that are highly
expressed in neuroendocrine tumors. Cytotoxic assays of the
conjugate show promising selectivity for cell lines overexpressing
somatostatin receptors.
Conclusions
Many cryptophycin derivatives have been isolated from natural
sources or have been obtained by total synthesis in order to
provide extensive SAR data. The eminent biological activity of some
cryptophycin analogs especially against MDR tumors renders them
promising candidates for treatment of such tumors. Although
cryptophycin-52 failed in clinical phase II studies, there is still an
interesting perspective for the application of cryptophycin
derivatives as bioconjugates in tumor-targeting approaches.
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